S
Salsa Biotherapeutics develops site-specific conjugation technology for creating more stable and scalable Antibody Drug Conjugates (ADCs). Their proprietary small molecule linker forms a stable covalent bond, enabling precise cargo attachment to avoid off-target toxicity associated with current ADC methods. This platform also facilitates the creation of dual-cargo ADCs to overcome drug resistance in cancer therapy.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Salsa Biotherapeutics develops site-specific conjugation technology for creating more stable and scalable Antibody Drug Conjugates (ADCs). Their proprietary small molecule linker forms a stable covalent bond, enabling precise cargo attachment to avoid off-target toxicity associated with current ADC methods. This platform also facilitates the creation of dual-cargo ADCs to overcome drug resistance in cancer therapy.